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Abstract
Glucose management in intensive care unit (ICU)
patients has been a matter of debate for almost two
decades. Compared to intermittent monitoring systems,
continuous glucose monitoring (CGM) can offer benefit
in the prevention of severe hyperglycemia and
hypoglycemia by enabling insulin infusions to be
adjusted more rapidly and potentially more accurately
because trends in glucose concentrations can be more
readily identified. Increasingly, it is apparent that a
single glucose target/range may not be optimal for
all patients at all times and, as with many other aspects
of critical care patient management, a personalized
approach to glucose control may be more appropriate.
Here we consider some of the evidence supporting
different glucose targets in various groups of patients,
focusing on those with and without diabetes and
neurological ICU patients. We also discuss some of the
reasons why, despite evidence of benefit, CGM devices
are still not widely employed in the ICU and propose
areas of research needed to help move CGM from the
research arena to routine clinical use.
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care, Monitoring
Background
The story of tight glucose control in the intensive care
unit (ICU) dates back to the publication of the first of
the Leuven studies [1]. This study showed reduced mor-
tality rates in surgical ICU patients who were managed
according to a protocol that strictly controlled blood
glucose levels using an insulin infusion. The study was
conducted on a background of increasing evidence for a
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potentially harmful effect of stress hyperglycemia on
morbidity and mortality, and triggered a surge of interest
among intensivists worldwide who started to pay more
attention to blood glucose concentrations. As with other
parameters that are regularly monitored in the ICU, the
concept of continuous monitoring was soon advanced
for blood glucose. It was suggested that this approach
would offer benefit compared to intermittent monitoring
systems, enabling insulin infusions to be adjusted more
rapidly and potentially more accurately because trends
in glucose concentrations could be more readily identi-
fied. However, despite initial excitement and agreement
by most intensivists that glucose concentrations should
be kept lower than they used to be (prior to 2001) and
that continuous glucose monitoring (CGM) systems may
be superior to intermittent measurements for this pur-
pose, only one device is in clinical use in Europe, and
none yet in the United States.
In this review, based on dialog among 12 leading ex-
perts in this field, we will consider some of the clinical
areas of ongoing discussion regarding CGM in the ICU,
including the need for different glucose targets in differ-
ent patient populations, and how this technology can be
moved from the research arena into routine clinical use.
Different targets for different situations
The exciting results of the single-center Leuven studies
[1, 2] were not confirmed in subsequent multicenter
randomized controlled trials (RCTs) [3–5], even when
computerized tools to facilitate tight glucose control
were used [6, 7]. However, these multicenter RCTs had
several limitations, including that the monitoring tech-
nology used may have been associated with analytic in-
accuracy; that the monitoring frequency was suboptimal,
increasing the likelihood of “missed” hypoglycemic and
hyperglycemic events; and that the clinical teams were
not as well trained as the Leuven team. These issues led
to a variable and often low proportion of time within the
targeted blood glucose range. Moreover, RCTs are
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notoriously difficult to conduct in the heterogeneous
ICU population and have rarely demonstrated an impact
of any intervention on mortality [8, 9].
Indeed, as the glucose story has unfolded it has be-
come apparent, as in many other areas of intensive care,
that one size does not fit all. Different types of patient
may have different needs in terms of glucose control,
making it difficult to demonstrate overall benefit in large
heterogeneous trials. For example, observational data
support the importance of glycemic control in patients
admitted to the ICU following trauma [10–12]. In the
predefined trauma subpopulation of the NICE-SUGAR
trial (n = 888/6028), there was a trend toward reduced
mortality in the patients treated with the “tight” blood
glucose target (odds ratio 0.77 (95% confidence interval
0.50–1.18)) [3]. Moreover, patients treated with systemic
glucocorticoids (n = 1997/6019), an additional subgroup
from this trial, also demonstrated a trend toward reduced
mortality (odds ratio 0.88 (95% confidence interval 0.66–
1.19)) when receiving intensive glucose control [3].
Here we consider two additional groups as examples
of categories of patients in whom optimal blood glucose
concentrations may differ from those of other types of
patient: patients with diabetes and neuro-ICU patients.
Patients with versus those without diabetes
Few studies have examined the impact of stress hyper-
glycemia and tight glucose control in critically ill pa-
tients with diabetes and there are currently no data from
interventional RCTs that have specifically studied this
population. Some subgroup analyses from the large mul-
ticenter RCTs in general ICU populations reported no
differences in effect between patients with and those
without diabetes [3, 5, 6], while others demonstrated
mortality benefit mainly in patients without diabetes
[13]. A post-hoc analysis of the adult Leuven studies re-
vealed no mortality benefit from tight blood glucose
control in the subgroup of patients with diabetes, in
contrast to all other subgroups, but there was a trend to-
ward reduced morbidity [14].
Observational data suggest that the independent asso-
ciation of hyperglycemia with mortality in the critically
ill is robust in patients without diabetes but not so in
those with diabetes [15, 16]. Other work has demon-
strated that a long time in range (70–140 mg/dl) is inde-
pendently associated with survival in patients without
diabetes but not in those with diabetes [17].
In addition to differences between patients with and
without diabetes, there may also be differences depend-
ing on the degree of premorbid glycemic control in pa-
tients with diabetes. Indeed, the glycemic threshold at
which the counterregulatory mechanisms to control
blood glucose concentrations are activated is higher in
patients with poorly controlled diabetes than in those
with well-controlled diabetes or without diabetes [18].
Egi et al. [19] reported that the time-weighted average
blood glucose concentration in patients with high gly-
cated hemoglobin (HbA1c) was higher in survivors than
in nonsurvivors, suggesting that conventional blood glu-
cose targets may not be appropriate in patients with
poorly controlled diabetes. The same group recently re-
ported that the higher the HbA1c level prior to ICU ad-
mission, the higher the risk of death in patients with
moderate (40–69 mg/dl) and severe (<40 mg/dl)
hypoglycemia [20]. Should glucose targets in the ICU
therefore be adjusted according to HbA1c levels? Two
recent small pilot studies from Australia in critically ill
patients with diabetes and HbA1c > 7% tested two glucose
targets (6–10 mmol/l (108–180 mg/dl) and 10–14 mmol/l
(180–252 mg/dl)) and demonstrated reduced glucose vari-
ability [21] and reduced “relative” hypoglycemia (defined
as blood glucose values < 30% predicted mean glycemia)
[22] in patients with the loose target. A recent single-
center, 2-year, before–after investigation evaluated two
blood glucose targets: 80–140 mg/dl for patients without
diabetes and those with diabetes and HbA1c < 7%, versus
110–160 mg/dl for patients with diabetes and HbA1c >
7%; there was a reduction in severity-adjusted mortality in
the patients with diabetes [23].
Summary and recommendations/food for thought/future
studies
Data therefore suggest that the optimal blood glucose tar-
get may be higher in patients with preexisting diabetes
compared to those without. However, further study is
needed to define the optimal level, because too high a level
may also be associated with complications, such as infec-
tion. Importantly, most of the published data in this area
are from studies using intermittent glucose testing, and
newer data using CGM techniques should provide more
information including the importance of glucose variability
and time in range for patients with and without diabetes.
The effects of insulin resistance also need to be taken
into account. HbA1c levels should be measured in all crit-
ically ill patients and care taken to avoid relative
hypoglycemia in those with poor preadmission glucose
control. However, the precise definition of “relative
hypoglycemia” and whether it should be based on some
measure of chronic baseline glucose or on the acute base-
line remain unclear; the time factor over which the relative
hypoglycemia occurs may also be important. The achieve-
ment of a fixed percentage decrease in blood glucose (i.e.,
the incidence of “relative hypoglycemia”) will also be influ-
enced by the target glycemic level. A large multicenter
trial (NCT02244073) comparing a blood glucose target
based on the admission HbA1c value to standard of care
has been completed recently.
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Neurointensive care patients
Glucose is particularly important in the brain because
the brain has high energy requirements and limited glu-
cose reserves. In microdialysis studies in neuro-ICU pa-
tients, tight glucose control was associated with reduced
cerebral glucose and an increased risk of cerebral meta-
bolic distress [24–27]. Hypoglycemia can cause second-
ary brain injury and should be avoided in these patients.
However, hyperglycemia can enhance brain injury and
various observational studies have demonstrated in-
creased mortality associated with hyperglycemia in pa-
tients with traumatic brain injury (TBI) [28–30] and
intracerebral hemorrhage [31–33].
Prospective data support the rationale of controlling
glucose concentrations within specific ranges in neuro-
logical patients. In a subanalysis of 63 patients with iso-
lated brain injury from the first Leuven study [1], van
den Berghe et al. [34] reported that insulin therapy tar-
geting a blood glucose of 80–110 mg/dl was associated
with reduced intracranial pressure, reduced need for va-
sopressors, fewer seizures, and better 1-year functional
outcomes than a target blood glucose > 200 mg/dl. In a
before–after analysis of an ICU database, tight glucose
control (targeting blood glucose between 80 and
140 mg/dl) reduced the odds of a poor outcome com-
pared to conventional glucose control (targeting blood
glucose < 200 mg/dl) in patients with aneurysmal sub-
arachnoid hemorrhage [35]. However, in a 24-month
follow-up of patients with TBI included in the NICE-
SUGAR study, neurological outcomes and survival
rates were similar in the intensive and conventional
groups [36].
Several prospective trials have compared “tight” versus
“conventional” glucose control protocols specifically in
critically ill patients with neurological conditions [37], in-
cluding those with TBI [38–41], subarachnoid hemorrhage
[42], stroke [43], and neurosurgery [44]. Most of these
studies reported increased rates of hypoglycemia in pa-
tients in the tight control arm with little or no impact on
mortality or neurological outcomes, although some re-
ported reduced infection rates with tight control [40, 42,
44]. These studies are difficult to compare because of
different patient populations, and different glucose tar-
gets within the tight and the conventional groups. A
meta-analysis of 16 RCTs reported that tight glucose
control was associated with improved neurological out-
comes, but only when the control group target glucose
was >200 mg/dl [45].
Summary and recommendations/food for thought/future
studies
Currently available data therefore suggest that tight
compared to conventional glucose control has little im-
pact on neurological or mortality outcomes in neuro-
ICU patients, although it may be associated with a de-
crease in infectious complications. Interestingly, in a
retrospective analysis, Meier et al. [46] reported that a
blood glucose target of 3.5–6.5 mmol/l (63–117 mg/dl)
during the first week in patients with TBI was associated
with significantly elevated intracranial pressure, in-
creased norepinephrine requirements, and a trend to-
ward increased mortality compared to a target of 5–
8 mmol/l (90–144 mg/dl), whereas in the second week
the lower target seemed more beneficial. It may there-
fore be that glucose concentrations should be kept at
higher levels during the early phase of TBI, and possibly
other acute neurological conditions, and lower targets
used at later stages. Further study is needed to clarify
this issue.
Given the possible negative impact of hypoglycemia
on secondary brain injury, depending on its severity and
duration, the traditional cutoff values for hypoglycemia
may need to be reconsidered and increased in these pa-
tients. The differences between patients with and with-
out diabetes also need to be taken into account when
considering appropriate glucose targets for neuro-ICU
patients. There are few data available, but Bosarge et al.
[30] reported that the association between hypergly-
cemia and mortality in patients with TBI was not present
in patients with diabetes as defined by known history or
admission HbA1c > 6.5%.
Design of future studies
Quality clinical studies are essential for continued pro-
gress in the field of glucose control and different types
of study can be considered, the key features and attri-
butes of which are summarized in Table 1.
Randomized controlled trials
The apparent failure of multicenter RCTs to reproduce
the positive findings of the original Leuven studies has
dampened enthusiasm for tight glucose control. How-
ever, although RCTs remain the best way to take into ac-
count the multiple factors that can influence the
response to any therapeutic intervention, this study de-
sign has known limitations in the heterogeneous critic-
ally ill patient population [9]. Moreover, glycemic
control is different in many ways from other interven-
tions in the ICU, including that it is highly dependent
on the chosen protocol and the training (and enthusi-
asm) of the staff operating the protocol. Glycemic con-
trol is also a continuous intervention, not a one-off
event, such as, for example, aspirin administration in
myocardial infarction. Therefore, its quality throughout
the process of care is crucial, as well as more difficult to
obtain. Because of the complexity of managing blood
glucose during the course of critical illness, we propose
that study design should include a phase I period in
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which the study centers adopt the intervention and show
they are capable of achieving an adequate time in the
targeted blood glucose range. Only after this ability has
been demonstrated should a center be allowed to partici-
pate in randomization. Regular review of glucose control
performance throughout the trial is also required.
Observational studies
Observational studies remain a key method to generate
hypotheses for future clinical trials. As such, recent stud-
ies have begun to explore more personalized approaches
to glycemic control based on observational data. For ex-
ample, in a recent, prospective before–after study, Krins-
ley et al. [23] studied different blood glucose targets in
patients with and without diabetes and in patients with
diabetes and HbA1c levels <7% and >7%, based on re-
sults from observational studies [16, 19, 47]. They com-
pared a blood glucose target of 90–120 mg/dl for all
patients in the “before” period with a dual target in the
“after” period according to the presence of poorly con-
trolled diabetes (80–140 mg/dl for patients without dia-
betes and patients with diabetes and HbA1c < 7%, and
110–160 mg/dl for patients with diabetes and HbA1c >
7%). The results showed similar mortality rates in the
two periods for nondiabetic patients, but decreased
severity-adjusted mortality in the “after” period in both
groups of diabetic patients.
Large databases could also be used to explore ques-
tions related to glycemic control, and collaboration be-
tween centers should be encouraged to stimulate
further research in this field. Ideally such databases
should be large, and contain essential demographic
data, severity scores, hospital outcomes, a complete set
of glucose measures including the key glucose metrics,
nutritional information, and HbA1c concentrations. As
experts in this field reach agreement on the optimal
metrics and outcomes that should be reported [48, 49],
studies will begin to include a standard set of data,
making it easier to combine datasets and create large
databases for analysis.
Individual patient data meta-analysis
Meta-analysis is a statistical technique in which data
from multiple trials are combined. However, when the
trials included in a meta-analysis include heterogeneous
groups of patients, meta-analysis may be impossible to
conduct or give inaccurate results. An alternative ap-
proach is to perform individual patient data meta-
analysis [50]. This technique has the advantages that
greater power is provided than by aggregate study meta-
analyses, primary data can be validated, and certain ana-
lyses which can only be conducted on individual data
(e.g., time-to-event analyses) can be performed. How-
ever, such studies involve a huge amount of work syn-
thesizing the individual raw patient data and returning
to the original data if certain variables are not recorded
in the publication. An individual data meta-analysis of
RCTs in this field has recently been completed and the
results are eagerly awaited. Nevertheless, this analysis
will be confounded by the same limitations as the ori-
ginal RCTs, including, but not limited to, a short time in
the targeted blood glucose range and high rates of
hypoglycemia among treated patients.
Table 1 Summary of trial designs
Trial design type Purpose Limitations Comments, recommendations
Randomized controlled trial To determine proof of causality Heterogeneous patient populations
reduce ability of the trial to ascertain
differences in treatment effect.
Logistic burden and cost
Participating centers should have a
phase-in period that allows
demonstration of the capacity of the
center to perform the study safely
and effectively.
Use of a smaller, well-defined, and
homogeneous population may
increase the probability of determining
a true treatment effect
Observational study Hypothesis generation Do not provide proof of causality Collaborations among centers with
large databases.
Standardization of reporting metrics
Individual patient meta-analysis To avoid the limitations and
complications inherent in comparing
disparate studies.
Allows interpretation of patient-
specific events that would not
normally be identified in aggregate
trial data
Hugely time and resource intensive The analysis will be confounded by
the same limitations as present in
the original trials
Cluster randomization To reduce variations in process of
care for complex interventions as a
confounding factor in randomized
controlled trials
Requires more complex statistical
methodology to account for the
effects of clustering
May be particularly suitable for
complex interventions, such as
glucose control in the critically ill
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Cluster randomization
Strict glucose control is complex and involves several
consecutive steps, each of which contains possible
sources of variability, from the technique used to meas-
ure the blood glucose to the algorithm used to adjust
the insulin dose, through to the training and motivation
of the staff operating the system [51]. As such, cluster-
randomized trials, in which groups of individuals rather
than single individuals are randomized to an interven-
tion, could represent an advantage over individual ran-
domized trials, reducing the impact of differences in
technique among different units. The disadvantages of
this approach are that more complex statistical method-
ology is needed to account for the effects of clustering
and more individuals may be needed overall to achieve
the same statistical power as in an individual RCT. In a
cluster-randomized study in a department of intensive
care comprised of four units, patients in two of the units
were randomized to standard glucose management and
the patients in the two other units were randomized to
CGM-guided glucose control. The randomized units’
treatment allocation was crossed over every month. The
results showed similar glucose control in terms of time
in range, but the time spent with glucose values <
70 mg/dl was reduced in the CGM-guided patients [52].
Moving forward … and how to keep the industry
on board?
There is now a broad base of evidence to support the use
of CGM devices as a means of facilitating glucose control
and decreasing nursing workload in ICU patients. Yet,
despite more than $700 million spent by the industry on
developing CGM devices, they remain largely experimen-
tal in the ICU and although several have FDA approval for
use in noncritically ill patients, the only device that re-
ceived FDA approval for critically ill patients is not mar-
keted and is not in clinical use. Only one device is
currently in clinical use in Europe [53].
So what are the priorities for the future in terms of en-
couraging more widespread use of these devices and en-
suring continued industry investment such that FDA/CE
approval can be obtained?
1. Accuracy is clearly important (and essential in terms
of licensing). Many of the devices reported in peer-
reviewed literature (using different probe location
sites and measurement techniques) fail to meet the
mean absolute relative difference (MARD) point
accuracy standard adopted by a previous consensus
panel [54]. One exception is the Optiscanner®
(OptiScan Biomedical Corporation, Hayward, CA,
USA), which has been reported to have MARD <
10% [53, 55], although other consensus requirements
for CGM devices were not met or not reported.
Importantly, comparisons, including MARD and
Clark error grids, are based on evaluation of
differences in values at a single time point, and
do not take the trend factor into account. Yet the
trends in glucose concentrations provided by CGM
can influence insulin dosing and thus glycemic
control. Thus, when comparing CGM devices, trend
accuracy as well as point accuracy needs to be
compared and reported. These assessments should be
independent because one can have perfect trend
correlation and poor point accuracy if the values are
simply shifted. One possible method of reporting
trend accuracy independently of point accuracy is the
trend compass [56].
When considering accuracy in CGM, the degree of
sensor drift should also be quantified and taken into
account. Drift is the tendency of such devices to
report increasingly erroneous values due to changes
in sensor condition or patient milieu at the insertion
site [57, 58] and may mask clinically important
trends in glucose concentrations.
2. As each new study is published, we learn more
about how current systems can be improved. For
example, a recent study reporting on the safety,
accuracy, and reliability of an intravenous blood
glucose system demonstrated that more than half of
the sensors inserted had to be removed before the
end of the planned 72-hour study period [59].
Similarly in a RCT comparing the use of subcutaneous
CGM with frequent point-of-care measurements, only
177 of the 1954 patients initially screened were finally
included [60]. Also, in a study of an intravenous
microdialysis CGM technique, the authors were
surprised at the number of patients who did not have
suitable peripheral veins to use for insertion [61].
These practical issues are important and need to be
reported routinely so that they can be resolved and
the devices improved. Devices (monitoring system
and algorithms) also need to be user-friendly for the
nurses who will be operating them, not just for
research staff.
3. The evidence base supporting the clinical effectiveness
and efficiency of these systems (CGM plus algorithm)
in ICU patients is still small and a pragmatic
evaluation of systems in the clinical setting may
facilitate their more widespread adoption. In-silico
simulation has demonstrated that increased
frequency of monitoring improves blood glucose
control as assessed by reduced occurrence of
hypoglycemia, hyperglycemia, and glucose variability
[62, 63]. Importantly, these types of analyses
assess not only the device but the whole process,
including the protocol used to adjust insulin
infusion and the nurses operating it, key considerations
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when thinking about introducing such a system into
your ICU.
4. Cost is a key concern in the introduction of any new
technology and there are few cost-effective data for
CGM systems [60]. A potential method of reducing
the costs associated with CGM is to combine other
parameters that require accurate monitoring (e.g.,
blood lactate and hemoglobin) within the same
system. An alternative is to encourage collaborative
research among companies producing various
components of the glycemic control process (e.g.,
CGM device, software algorithm, etc.). Ideally, to
reduce costs involved when changing the insulin
algorithm, devices should not be restricted for use
with a single algorithm.
5. Further study is needed to define optimal glycemic
targets (ranges) in general ICU populations and in
some selected populations (e.g., patients with
diabetes, neurological injury, trauma, or sepsis), and
to consider at what time point in the disease process
these targets are most important. In addition, the
influence of the feeding regimen on the effectiveness
of strict glucose control remains unclear. The use of
GCM in such studies will help provide answers to
these questions.
Conclusion
We believe that the prevention of severe hyperglycemia
and hypoglycemia should be considered a strong object-
ive in all settings involving critically ill patients and that
CGM can contribute to safe, effective glucose manage-
ment. CGM, when combined with a validated insulin in-
fusion protocol that minimizes glycemic variability, can
help improve patient outcomes and reduce workload,
which may be cost-effective. Once reliable devices with
acceptable point accuracy are available at reasonable
running costs, CGM will be useful in all critically ill pa-
tients receiving strict glucose control. The optimal blood
glucose target remains unclear and may depend on the
studied patient population. As with any monitoring de-
vice, CGM cannot per se improve outcomes, but must
be combined with an effective algorithm and trained,
dedicated staff.
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